CSIMarket
 


Odonate Therapeutics Inc   (ODT)
Other Ticker:  
 

Odonate Therapeutics Inc 's Leverage Ratio

ODT's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 1.34%, Leverage Ratio fell to 0.48, below the Odonate Therapeutics Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2021, 337 other companies have achieved lower Leverage Ratio than Odonate Therapeutics Inc in the III Quarter 2021. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2021 from 122 to 1461 .

Explain Leverage Ratio?
Who are ODT Customers?
What are ODT´s Total Liabilities?


ODT Leverage Ratio (Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Equity Change -56.9 % -19.82 % -22.14 % -16.12 % -11.06 %
Y / Y Total Liabilities Change 3.03 % 24.91 % 40.53 % 19.66 % 17.56 %
Leverage Ratio MRQ 0.48 0.4 0.36 0.23 0.2
ODT's Total Ranking # 1461 # 122 # 808 # 877 # 154
Seq. Equity Change -15.66 % -19.64 % -22.66 % -17.79 % 56.9 %
Seq. Total Liabilities Change 1.34 % -9.66 % 18.39 % -4.94 % 22.86 %



Leverage Ratio third quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 338
Healthcare Sector # 634
Overall Market # 1461


Leverage Ratio Statistics
High Average Low
92.02 7.47 0.06
(Dec 31 2012)   (Mar 31 2018)




Financial Statements
Odonate Therapeutics Inc 's Equity $ 71 Millions Visit ODT's Balance sheet
Odonate Therapeutics Inc 's Total Liabilities $ 34 Millions Visit ODT's Balance sheet
Source of ODT's Sales Visit ODT's Sales by Geography


Cumulative Odonate Therapeutics Inc 's Leverage Ratio

ODT's Leverage Ratio for the trailling 12 Months

ODT Leverage Ratio

(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Equity TTM Growth -56.9 % -19.82 % -22.14 % -16.12 % -11.06 %
Y / Y Total Liabilities TTM Growth 3.03 % 24.91 % 40.53 % 19.66 % 17.56 %
Leverage Ratio TTM 0.35 0.28 0.25 0.22 0.2
Total Ranking TTM # 21 # 20 # 18 # 18 # 17
Seq. Equity TTM Growth -15.66 % -19.64 % -22.66 % -17.79 % 56.9 %
Seq. Total Liabilities TTM Growth 1.34 % -9.66 % 18.39 % -4.94 % 22.86 %


On the trailing twelve months basis Due to the net new borrowings of 1.34% during the trailing twelve months finishing in the III Quarter 2021, cumulativeLeverage Ratio improved to 0.35, below the Odonate Therapeutics Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry ODT recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2021, compared to the prior period, from 20 to 21.

Explain Leverage Ratio?
Who are ODT Customers?
What are ODT´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 21


trailing twelve months Leverage Ratio Statistics
High Average Low
5.66 0.59 0.08
(Dec 31 2016)   (Mar 31 2018)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2021, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2021 MRQ Total LiabilitiesSep 30 2021 MRQ Equity
Amryt Pharma Plc  1.29 $ 459.396  Millions$ 356.661  Millions
Gossamer Bio Inc   1.28 $ 217.229  Millions$ 169.809  Millions
Ocular Therapeutix Inc   1.27 $ 110.490  Millions$ 87.340  Millions
Scopus Biopharma Inc   1.25 $ 2.237  Millions$ 1.794  Millions
Zealand Pharma A  1.23 $ 1,139.826  Millions$ 927.803  Millions
Zogenix Inc   1.22 $ 272.688  Millions$ 224.299  Millions
Evolus Inc   1.21 $ 117.816  Millions$ 97.404  Millions
Phathom Pharmaceuticals Inc   1.19 $ 123.616  Millions$ 103.481  Millions
Landec Corporation  1.19 $ 230.591  Millions$ 193.865  Millions
Unity Biotechnology Inc   1.18 $ 67.954  Millions$ 57.737  Millions
Verrica Pharmaceuticals Inc   1.17 $ 47.904  Millions$ 40.852  Millions
Kineta Inc   1.15 $ 37.352  Millions$ 32.469  Millions
Royalty Pharma Plc  1.14 $ 11,829.288  Millions$ 10,386.634  Millions
Aveo Pharmaceuticals Inc   1.13 $ 57.834  Millions$ 51.234  Millions
Cv Sciences Inc   1.10 $ 12.311  Millions$ 11.142  Millions
Ardelyx Inc   1.10 $ 89.416  Millions$ 81.432  Millions
Biodelivery Sciences International Inc   1.09 $ 133.295  Millions$ 122.775  Millions
Pharming Group N v   1.06 $ 204.399  Millions$ 192.916  Millions
Aytu Biopharma Inc   1.04 $ 116.229  Millions$ 111.500  Millions
Perrigo Company Plc  1.03 $ 5,350.400  Millions$ 5,182.400  Millions
Lifevantage Corp  1.03 $ 38.287  Millions$ 37.310  Millions
Elanco Animal Health Inc  1.02 $ 7,841.000  Millions$ 7,682.000  Millions
Innoviva Inc   0.99 $ 484.428  Millions$ 491.805  Millions
Rvl Pharmaceuticals Plc  0.98 $ 53.762  Millions$ 54.750  Millions
Global Blood Therapeutics Inc.  0.97 $ 299.378  Millions$ 308.300  Millions
Galapagos Nv  0.96 $ 2,855.774  Millions$ 2,960.565  Millions
Arvinas Inc   0.96 $ 787.128  Millions$ 817.737  Millions
Syros Pharmaceuticals Inc   0.96 $ 101.983  Millions$ 106.060  Millions
Novartis Ag  0.94 $ 63,973.000  Millions$ 67,822.000  Millions
Horizon Therapeutics Public Limited Company  0.93 $ 4,158.474  Millions$ 4,450.214  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com